Andrew Partheniou
Recent Articles about Awakn Life Sciences Corp.
Biotech at Good Entry Point for Investors, Analyst Says 12/20/2022
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report.
Co. Pursuing Ketamine for Addiction Forms Partnership 08/16/2022
In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report.
Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co. 07/13/2022
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.
© 2023 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
